IGF2R and endometrial cancer: Similarly, the Igf2r D1310 frameshift deletion mutation identified in our murine models is shared by 3.8% of MSI-H colorectal cancer patients, 3% of MSI-H endometrial cancer patients and 1.4% of MSI-H stomach cancer patients (Figure 1 G, I).